Comparative Pharmacology
Head-to-head clinical analysis: ALLERNAZE versus PROMETHAZINE VC PLAIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALLERNAZE versus PROMETHAZINE VC PLAIN.
ALLERNAZE vs PROMETHAZINE VC PLAIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist at histamine H1 receptors, preventing histamine-mediated symptoms such as itching, sneezing, and vasodilation.
Promethazine is a phenothiazine derivative with antihistaminic (H1 receptor antagonist), sedative, antiemetic, and anticholinergic effects. Phenylephrine is a sympathomimetic amine acting primarily on alpha-1 adrenergic receptors, causing vasoconstriction.
5 mg orally once daily at bedtime, maximum 10 mg per day.
Adults: 1 tablet (promethazine 6.25 mg, phenylephrine 10 mg) orally every 4-6 hours as needed, not to exceed 4 tablets in 24 hours.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours. Clinical context: Allows for twice-daily dosing in allergic rhinitis; steady-state reached in 2-3 days.
Terminal elimination half-life is approximately 9–16 hours (mean ~12 hours) in adults; may be prolonged in hepatic impairment or elderly patients.
Primarily renal (70-80% as unchanged drug and metabolites), with approximately 5-10% biliary/fecal elimination.
Primarily renal as inactive metabolites; approximately 70-80% excreted in urine, with about 20-30% in feces via biliary secretion. Less than 1% excreted unchanged.
Category C
Category A/B
Antihistamine
Antihistamine / Antiemetic